Week 4(SINUS-52; other secondary endpoint)
IMPROVEMENT
With DUPIXENT
with placebo1,a
Week 24(SINUS-52; other secondary endpoint)
IMPROVEMENT
With DUPIXENT
with placebo1,b
Week 52(SINUS-52; other secondary endpoint)
IMPROVEMENT
With DUPIXENT
with placebo1,c
aWeek 4 in SINUS-52. LSM difference between DUPIXENT 300 mg Q2W + INCS (n=150) vs placebo + INCS (n=153): -10.57 (95% CI: -14.47,
-6.66) (-18.97 from a baseline score of 50.16 vs -8.40 from a baseline score of 53.48, respectively).1
bWeek 24 in SINUS-52. LSM difference between DUPIXENT 300 mg Q2W + INCS (n=150) and placebo + INCS (n=153): -16.76 (95% CI:
-20.85, -12.67) (-27.08 from a baseline score of 50.16 vs -10.32 from a baseline score of 53.48, respectively).1
cWeek 52 in SINUS-52 (key secondary endpoint). LSM difference between DUPIXENT 300 mg Q2W + INCS (n=150) vs placebo + INCS
(n=153): -20.96 (95% CI: -25.03, -16.89) (-29.84 from a baseline score of 50.16 vs -8.88 from a baseline score of 53.48, respectively).1
Turn to DUPIXENT to improve a range of CRSwNP
symptoms and QoL
measures2
SNOT-22 measures
the QoL of CRSwNP
patients3
The SNOT-22 score is calculated from a patient questionnaire where 22 symptoms are rated from 0 (“no problem”) to 5 (“as
bad is it can be”) based on the severity and frequency of each particular item.2
The study was not designed to measure the impact of treatment on the individual components. Therefore, improvement in
the total aggregate SNOT-22 score does not necessarily correlate with a positive effect on each individual item or domain.
Sleep
- Difficulty falling
asleep - Wake up at night
- Lack of a good
night's sleep
Function
- Wake up tired
- Fatigue
- Reduced
productivity - Reduced
concentration
Ear/Facial
- Ear fullness
- Dizziness
- Ear pain
- Facial pain/
pressure
Emotional
- Frustrated/
restless/irritable - Sad
- Embarrassed
Nasal
- Need to blow nose
- Nasal blockage
- Sneezing
- Runny nose
- Cough
- Post-nasal discharge
- Thick nasal discharge
- Decreased sense of
smell/taste
22-item Sino-Nasal Outcome Test (SNOT-22) score (range 0-110); reduced score indicates improvement.2
INCS, intranasal corticosteroid; LSM, least squares mean; Q2W, once every 2 weeks; QoL, quality of life.